Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs

Several highly efficacious vaccines for SARS-CoV-2 have been developed and are used in the population. However, the current production capacity cannot meet the global demand. Therefore, additional vaccines—especially ones that can be produced locally and at low cost—are urgently needed. This work d...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jesús Horacio Lara-Puente, Juan Manuel Carreño, Weina Sun, Alejandro Suárez-Martínez, Luis Ramírez-Martínez, Francisco Quezada-Monroy, Georgina Paz-De la Rosa, Rosalía Vigueras-Moreno, Gagandeep Singh, Oscar Rojas-Martínez, Héctor Elías Chagoya-Cortés, David Sarfati-Mizrahi, Ernesto Soto-Priante, Constantino López-Macías, Florian Krammer, Felipa Castro-Peralta, Peter Palese, Adolfo García-Sastre, Bernardo Lozano-Dubernard
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2021
Materias:	Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/d47ce303ae344529b5dda46a5d3fc757
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs

Ejemplares similares